Reduced Notch2-expression on ‘classical’ (CD14+) monocytes has proved its potential as biomarker to predict drug-neutralizing antibody development in IFNβ-naive MS patients, and a functional link between Notch2-activity and the differentiation into ‘non-classical’ (CD14lowCD16+), pro-inflammatory monocytes was indicated and certainly advocate future studies (190). This evidence concerns the gene NOTCH2 and myeloid sarcoma.